MONTREAL, September 28, 2017 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic HBV and hepatitis delta virus (HDV) co-infection, announced today the publication of its REP 301 study on the activity of REP 2139 and pegylated interferon α-2a (pegIFN) in The Lancet Gastroenterology & Hepatology (www.replicor.com/science/publications).
The REP 301 study assessed the safety and efficacy of REP 2139 combined with pegIFN in patients with chronic HBV / HDV co-infection. This study demonstrated several key breakthroughs in this patient population including: REP 2139-mediated HBsAg reduction to below 1IU/mL dramatically potentiates the activity of pegIFN, that profound functional control of both HBV and HDV can be established in a high proportion of patients, that this function control persists for 1 year after therapy was withdrawn and is accompanied by normalization of liver function. The critical importance of HBsAg reduction below 1IU/mL was emphasized by the lack of potentiation of pegIFN in three patients who achieved HBsAg levels as low as 16.4, 5.74 and 1.88 IU/mL during exposure to pegIFN.
Dr. Vaillant, CSO of Replicor commented, “We are pleased to see the results of the REP 301 study published in The Lancet family of journals. This publication demonstrates a real therapeutic advance for patients with the most aggressive form of viral hepatitis, for which there is currently no effective treatment option”, commented Dr. Andrew Vaillant, CSO of Replicor who added, “we are confident that the breakthrough results we have achieved in the REP 301 study will be significantly improved upon using the more mature REP 2139-based combination regimen currently being validated in the REP 401 protocol.”
Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV co-infection. For further information about Replicor please visit our website at www.replicor.com.
* The study is conducted by Clinical Accelerator